Ceregene Acquired By Sangamo BioSciences

San Diego-based Ceregene, a startup developing gene-therapy based products for treating Parkinson's and Alzheimer's disease, has been acquired by Richmond, California-based Sangamo BioSciences. Sangamo said it will issue 100,000 shares of its common stock--approximately $1.0M--to acquire Ceregene, plus unspecified earn-out. Ceregene had been venture backed by Alta Partners, California Technology Ventures, Cell Genesys, Hamilton BioVentures, Investor Growth Capital Ltd., and MPM Capital, and had raised north of $71M in funding.